Pharmacy Investors, LLC, a member of a group that previously held a 10% stake in Guardian Pharmacy Services, Inc. (NASDAQ: GRDN), sold 827,636 shares of the company's Class A Common Stock on March 20, 2026, according to a Form 4 filing submitted to the Securities and Exchange Commission. The filing specifies a per-share sale price of $29.6825, producing gross proceeds of $24,566,305 for the transaction.
The Form 4 notes that the disposal was carried out under an underwriting agreement dated March 18, 2026. After the March 20 sale, Pharmacy Investors, LLC remains a direct holder of 1,035,928 shares of Guardian Pharmacy Services.
The timing of the sale has drawn attention because GRDN shares have since climbed to $37.57, trading in the vicinity of a 52-week high of $38.12. Data cited in the filing indicates the stock has returned 75.6% over the prior 12 months. The company now carries a market capitalization of $2.36 billion, while an InvestingPro assessment referenced in the filing suggests the stock is trading above its Fair Value.
Guardian Pharmacy Services recently reported fourth-quarter results that outperformed expectations. The company posted revenue of $397.6 million for the quarter, ahead of the consensus estimate of $390.0 million. Adjusted EBITDA came in at $39.5 million, surpassing the Street estimate of $28.8 million.
Following the quarterly release, two brokerages adjusted their outlooks. Raymond James raised its price target for Guardian Pharmacy Services to $40 while maintaining an Outperform rating. Truist Securities lifted its price target to $38, citing the company’s strong quarterly performance and an upward revision to its fiscal 2026 guidance.
Separately, Guardian completed an underwritten public offering totaling 6,900,000 shares of its Class A common stock. The offering consisted of 5,880,000 shares sold by certain existing stockholders and 1,020,000 newly issued shares sold by the company as part of a synthetic secondary transaction. The public offering was priced at $31 per share, subject to an underwriting discount.
From the net proceeds attributable to the company’s portion of the offering, Guardian repurchased 1,020,000 outstanding shares, which were subsequently canceled. These capital markets actions form part of a series of strategic financial moves disclosed by the company alongside its quarterly operating results.
Context and implications
The Form 4 filing documents a sizable insider-related sale executed under an underwriting agreement, and the company’s recent operating results and follow-on equity offering together sketch a picture of active balance-sheet and market activity. The sale, the results beat, the analyst price target changes, and the offering with concurrent repurchase and cancellation of shares are all disclosed items that market participants can review in their investment assessment of Guardian Pharmacy Services.